.
London, UK (PRWEB) 12 มกราคม 2012
Studies
new content alliances and M & A Yearbook 2012 CurrentPartnering. Was published recently, the Bureau of Printing, Ltd
.Details for
:
.Post
: cooperation and M & A Yearbook 2012.
Date: January 2012.
Home />
Price />
report is intended to ensure full understanding and unprecedented access to a range of partnerships and M &. Proposals and agreements leading health care company in 2011 from pole to pole, as well as providing forecasts of dealmaking in 2012.
.The report
.
? Trends in dealmaking in the industry since 2007 BioPharma?;
? Analysis of the partnership and M &. The management structure;
? Comprehensive directory of partnerships and M &. The proposal in 2011;
? Links to online access to more than 3,500 partners and 600 M &. Proposals;
? Leading M &. Proposals for cost in 2011;
?.
most active in the report of M & dealmakers and 2011 Contents:
.Executive
Information
.Chapter 1 Introduction
.Chapter 2 Overview of partnership activities in 2011
.2,1
introduced.
2,2 of the Partnership in 2011.
2.2.1 All partners, by volume.
2.2.2 of the Agreement on Partnership in dollars.
2,3 proposed an alliance in 2011, 10.
2.3.1 Eli Lilly, Boehringer Ingelheim: licensing and development agreement and the options include the joint development of insulin analogues.
2.3.2 Lundbeck Otsuka: The company develops and co-promotion agreement for up to five innovative products in the field of psychiatry and neurology.
2.3.3 Eli Lilly, Amylin: End Bydureon (Exenatide) once a week.
2.3.4 Alios BioPharma text: the license agreement for the ALS-2200 ALS-2158.
2.3.5 Astellas Pharmaceuticals Aveo: R & D cooperation and trade agreements for tivozanib.
2.3.6 U.S. BioSolutions emergency service contracts and supply contracts for BioThrax.
2.3.7 Amgen Micromet: Joint R & D for BITE antibody against an unknown target solid tumors of three.
2.3.8 Servier Mirage: development of a target for miR-208 and miR-15/195.
2.3.9 Janssen Biotech Pharmacyclics: The joint development, licensing and marketing agreement for PCI-32765.
2.3.10 China Meheco: Agreement for the supply of drugs in Venezuela.
2,4 BioPharma Partner offer.
2,5 proposed by industrial partners.
2,6 offers its partners in development.
2,7 branch offers guidance.
2,8 partnership deals therapeutic area.
2,9 Partner terminate the Agreement in 2011
Chapter 3: Overview of M &. In 2011
.3,1
introduced.
3,2 m. Transactions for 2011.
3.2.1 M &. Activities by volume.
3.2.2 M &. Activities in accordance with the terms of dollars.
3,3 key M &. Proposal, 2011 10.
3.3.1 Express Scripts Medco Health Solutions: Physician Medco.
3.3.2 Johnson & Johnson, Synthes: provision of Synthes.
3.3.3 Takeda Nycomed: agreement providing Nycomed.
3.3.4 Gilead Sciences Pharmasset: provision of Pharmasset.
3.3.5 Danaher Beckman Coulter: the provision of Beckman Coulter.
3.3.6 Teva Head: The head of security agreements.
3.3.7 DuPont Danisco: the provision of Danisco.
3.3.8 Kinetic Partners Apax: kinetic software.
3.3.9 PPD Carlyle Group, Hellman &. Friedman: granting PPD.
3.3.10 Thermo Fisher Scientific Phadia: a contract for the supply of Phadia.
3,4 Bigpharma M &. Transactions for 2011.
3,5 M &. Tourist business in 2011
Chapter 4 Dealmakers
most active in 2011
.4,1
introduced.
4.2 The most active partners in 2011.
4,3 m and a job in 2011
Chapter 5 deals in value terms in 2011
.5,1
introduced.
5,2 Free is a leading partner in 2011.
5,3 m. Great deals in 2011
Chapter 6 Bigpharma
partner in 2011
.6,1
introduced.
6,2 Bigpharma related industries.
…
more research can be found at the publisher. CurrentPartnering.
.# # #
. clear = “all”.
Find More news Teva press .